CD274 and sarcoma: This may be due to the standardization process of testing, different antibodies used for PD-L1 detection, the number of proprietary companion diagnostics, different samples used for specific sarcoma subtypes, and the lack of clear definitions of a “positive” tumor in terms of PD-L1 staining by immunohistochemistry (IHC)50.